Proagio is under clinical development by ProDa BioTech and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Proagio’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Proagio Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Proagio is under development for the treatment of solid tumors including pancreatic cancer, prostate cancer, treatment-resistant cancers, including triple-negative breast cancer and liver cancer. It acts by targeting integrin alpha V beta 3.
Quick View Proagio LOA Data
|Highest Development Stage|